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Novelty and Impact: 
This study showed, for the first time in France, differences in incidence trends between 
possible Human papilloma virus (HPV)-related and HPV-unrelated head and neck cancers. 
This suggests an increasing incidence of head and neck cancers due to HPV infection. The 
difference was less marked in men as compared to women, most likely because of a higher 
contamination in the HPV-related group by cancers due to tobacco or alcohol consumption. 
  
 Abstract 
Human papilloma virus (HPV) has been recently recognised as a carcinogenic factor for a 
subset of head and neck cancers (HNC). In Europe, France has one of the highest incidence 
rates of HNC. The aim of this study is to explore changes in HNC incidence in France, 
potentially in relation with infection by HPV. 
HNC were classified into two anatomical groups: potentially HPV-related and HPV- 
unrelated. Trends over the period 1980-2012 were analysed by an age-period-cohort model 
based on data from eleven French cancer registries.  
Among men, the age-standardised incidence rate (ASR) of HNC decreased in both groups, 
but less so for HPV-related sites as compared to unrelated sites, especially in recent years 
(annual percentage change (APC) over the period 2005-2012 : -3.5% versus -5.4%). Among 
women, the ASR increased in both groups, but more rapidly for HPV-related as compared to 
unrelated sites (APC over the period 2005-2012: +1.9% versus -0.4%). This preferential 
growth of HPV-related versus unrelated HNC was observed in the cohorts born from 1930-
1935. 
The differences in trends between possible HPV-related and HPV-unrelated sites suggest an 
increasing incidence of HNC due to HPV infection. The difference was less marked in men 
as compared to women, most likely because of a higher contamination in the HPV-related 
group by cancers due to tobacco or alcohol consumption. The pattern observed is consistent 
with observations made in other countries, with studies of HPV prevalence in HNC and the 
evolution of sexual behaviour in France.  
  
 Introduction 
In Europe, head and neck cancers (HNC) (encompassing oral cavity, pharynx and larynx 
cancers) are the seventh most common group of cancers, with an estimated 139 500 cases 
diagnosed in 2012 and an estimated 63 500 deaths1. 
HNC incidence trends are usually correlated with the level of tobacco and alcohol 
consumption, the main well-known risk factors, which act synergistically. Other observed or 
suspected risk factors include diets low in fruit and vegetables, poor dental care, professional 
exposure to carcinogens, or viral infection with Epstein-Barr virus or human 
immunodeficiency virus2, 3. But in recent decades, a lot of countries have observed changes 
in the epidemiological pattern of a subset of these cancers: the United States4, 5, Canada6 
and Scandinavian countries7-9 have seen an increase in the incidence of oropharyngeal 
cancers, whereas the incidence of other HNC is decreasing or constant. For example, from 
Canadian Cancer Registry data, Forte et al. showed a significant increase of oropharynx 
cancers from 1992 to 2009 (annual percentage change-APC=2.7, p<0.001), in contrast, HNC 
overall incidence decreased between 1992 and1998 (APC=-3.0, p<0.01), then remained 
stable 6. This increase is linked by the researchers to increased infections by human 
papillomavirus (HPV) which has been recognised since 2007 by the International Agency for 
Research against Cancer (IARC) as a carcinogenic agent for the oral cavity and oropharynx. 
The evidence is strongest for squamous cell tumours arising from the tonsils, base of tongue 
and oropharynx10.  
The prevalence of HPV in oropharyngeal cancer varies from 40 to 80% in the US and from 
20% (countries where alcohol and tobacco consumption is frequent) to 90% (Sweden) in 
Europe10. The relative contribution of this risk factor in HNC incidence may be evolving 
rapidly: Swedish hospital studies have shown that the prevalence of HPV (detection of HPV 
DNA by polymerase chain reaction (PCR)) in tonsil cancer progressed from 68% in 2000-
2002 to 93% in 2006-200711 and in base of the tongue cancer from 58% in 1998-2001 to 
84% in 2004-20078. 
These epidemiological changes should receive attention because patients with HPV-positive 
oropharynx cancers have a better sensitivity to radio- and chemotherapy than HPV-negative 
patients and a better overall survival and progression-free survival 10, 12, 13. 
Changes in sexual behaviour may be associated with the increased prevalence of HPV-
infection in HNC 5, 10. 
 
France has one of the highest incidence rates of HNC in Europe1. Incidence is steadily 
decreasing in men and increasing in women14, 15. Studies have reported an overall HPV 
prevalence in oropharyngeal cancer (PCR) comprised between 30.4% and 65.4% 13, 16, 17 . 
However, the potential impact of HPV infection on incidence trends is unknown. The aim of 
this study is to explore changes in HNC incidence in France, potentially in relation with 
infection by HPV: we assessed differences in incidence between possible HPV-related and 
HPV-unrelated HNC for the period 1980 to 2012. 
 
Material and methods 
 
Incidence data 
Incidence data were provided by the eleven French general cancer registries of the 
Départements Bas-Rhin, Calvados, Doubs, Haut-Rhin, Hérault, Isère, Loire-Atlantique, 
Manche, Somme, Tarn and Vendée, which covered 8.7 million inhabitants. The database 
contains information on date of diagnosis and birthdate, gender, topography and morphology 
for each patient. The cases of HNC included in the study were invasive tumours diagnosed 
between the beginning of the registry (the earliest being 1975 for the Bas-Rhin cancer 
registry and the latest 1998 for the Loire-Atlantique cancer registry) and 2011 and were 
limited to squamous cell carcinomas, defined as International Classification of Disease for 
Oncology version 3 (ICDO-3) histology codes 8050-8076, 8078, 8083, 8084, 8094, 8123.  
 
Because information regarding the presence of HPV within the tumours is rarely available in 
medical records, we classified the HNC into two anatomical groups in accordance with 
molecular and epidemiologic data 18 and following previous studies 6, 19-21: potentially HPV-
related (HPV-R) cancers and HPV-unrelated (HPV-Unr) cancers.  
HPV-R cancers included the following sites (ICDO-3): Base of tongue (C01.9), Tonsil (C02.4, 
C09), Oropharynx (C10) and Waldeyer ring (C14.2). 
HPV-Unr cancers included the following topography codes (ICDO-3): Lip (C00), Tongue 
(C02 except C02.4), Gum (C03), Floor of mouth (C04), Palate (C05), Other and unspecified 
parts of mouth (C06), Pyriform sinus (C12), Hypopharynx (C13), Other and ill-defined sites 
(C14 except C14.2), Larynx (C32). 
 
Population data 
Population data were obtained from the Institut National de la Statistique et des Etudes 
Economiques (INSEE) tabulated by Département, sex, annual age and year from 1975 to 
2013, in order to estimate person-years up to 2012. 
 
Statistical analyses 
Incidence data were tabulated using 1-year intervals for age, period and cohort. Age-period-
cohort models were used to estimate national incidence trends for each sex and HPV group 
(related or unrelated), based on observed incidence data from the area covered by registries 
up to 2011, with a short-term projection to estimate incidence in 2012. The area covered by 
the registries was assumed to be representative of France. 
The following model was fitted: Log(Ka,c,d/ PYa,c,d)= αd+ s1(a)+ s2(c)+p2 , where Ka,c,d is the 
number of cases diagnosed at age a from cohort c in the département d, PYa,c,d is the 
corresponding person-years, p is the period of diagnosis (year), and αd represents a 
categorical effect of the département. Effects of age and cohort were modelled using 
smoothing splines, denoted by s1 and s2. The second-order period term p2 was introduced 
into the model only when it was statistically significant (likelihood ratio test, α = 1%). Note 
that introducing p2 is equivalent to introducing a linear age-cohort interaction.  
Incidence rates were age-standardised on the worldstandard population (ASR). The annual 
percentage change (APC) of the ASR over the period 1980-2012 was estimated using the 
formula λ2012= λ1980x(1+APC)32 , where λy is the ASR estimate for the year y. APC over the 
period 2005-2012 was estimated similarly. 
In addition, trends in the net probability of developing cancer (i.e. assuming that there are no 
competing causes of death) between 0 and 74 years by birth cohort were estimated. This 
indicator was estimated from the age-period-cohort model, with an extrapolation up to 74 
years for the recent cohorts. 
Analyses were performed using S-PLUS software, version 6.2  
 
Results 
 
Model selected  
For HPV-R HNC, the model retained was a simple Age-Cohort model for both men and 
women, while an Age-Cohort model with a second-order period term p2 was selected for 
HPV-Unr HNC in both men and women. 
 
Trends according to year  
In France, the estimated number of all cases of HNC was 12 972 in 2012, with 10 319 new 
HNC in men and 2 653 in women (Table 1). 
Incidence of both HPV-R and HPV-Unr HNC was higher among men than women.  
Among men, the age-standardised incidence rate of all HNC decreased but less so for HPV-
R sites (Figure 1). Overall, the APC was higher for HPV-R compared to HPV-Unr HNC 
(Table 1). The sharpest incidence decrease in both groups was seen in the most recent 
period (2005-2012). 
Among women, the age-standardised incidence rate of all HNC increased but more rapidly 
for HPV-R sites. Overall, the APC was higher for HPV-R compared to HPV-Unr HNC. For the 
recent period (2005-2012), the APC increased for HPV-R HNC while it remained stable for 
HPV-Unr HNC. 
During the period, the incidence sex ratio decreased from 19.8 to 3.9 for HPV-R HNC and 
from 19.8 to 4.9 for HPV-Unr. Among men, the median age at diagnosis increased for HPV-R 
and HPV-Unr sites from 1980 to 2012. Among women, the median age at diagnosis 
remained stable. Men with HPV-Unr HNC were diagnosed at younger ages than women. 
Patients with HPV-R sites were diagnosed at younger ages than HPV-Unr sites, especially 
among women.  
Among HNC, the proportion of HPV-R cancer cases increased from 23.7 % in 1980 to 29.5% 
in 2012 in men and from 22.9% to 31.4% in women. The percentage increased from the 
beginning of the nineties. It became higher in women compared to men at the end of the 
nineties. 
 
Trends according to birth cohort 
Regarding the probability of developing cancer between 0 and 74 years (Figure 2) by birth 
cohort (1920 to 1950), it has decreased in men by 30.7% (1.37% to 0.95%) for HPV-R HNC 
and by 47.4% for HPV-Unr HNC (4.18% to 2.20%). In women, the probability has tripled for 
HPV-R HNC (from 0.07% to 0.20%) and increased by 61.9% for HPV-Unr HNC (0.21% to 
0.34%). 
The ratio of net probability of developing cancer between 0 and 74 years for HPV-R vs HPV-
Unr HNC (Figure 3) has increased for both sexes, indicating an increasingly greater 
proportion of HPV-R cancers in relation to HPV-Unr cancers. Among men, the cumulative 
risk for HPV-R decreased less quickly than that for HPV-Unr HNC starting from the 1930 
cohort. Among women, starting from birth cohort 1935, the cumulative risk of HPV-R cancers 
increased more quickly than that of HPV-Unr cancers.  
 
Trends according to birth cohort and age 
The evolution of incidence rates by birth cohort (Figure 4) shows an overall decrease in 
incidence rate among men, whatever their age. However, incidence rates of HPV-R sites fell 
less rapidly than those of HPV-Unr sites in all age groups.  
Among women, an increase in incidence rate was observed in the oldest birth cohorts at all 
ages for HPV-R sites (Figure 4). With regard to HPV-Unr sites, incidence rate went up for the 
oldest birth cohorts then remained stable for the most recent cohorts at ages 60, 70 and 80 
years. For the most recent cohorts, incidence rate at 50 years has decreased slightly. 
 
Discussion 
Differences in incidence trends in HNC according to their potential association with HPV are 
being observed for both sexes, more markedly among women. Among women, the overall 
incidence of HNC was increasing but, for a recent calendar period, HPV-Unr HNC incidence 
remained stable whereas HPV-R HNC incidence was still increasing. In consequence, the 
proportion of HNC potentially related to HPV increased from 1980 to 2012, especially after 
1990. Among men, the overall incidence of HNC was decreasing, but less for HPV-R than 
HPV-Unr sites, leading to a slight increase in the proportion of HPV-R cancers. In both men 
and women, the main epidemiological changes concerning HPV-R cancers started in birth 
cohorts from1930-1935. 
 
Our study has several important strengths. To our knowledge, there has not been a previous 
study of the French population using cancer registry data to examine the incidence of HNC, 
taking into account a potential role of HPV. Furthermore, our study covered a long period (32 
years). The modelling adopted provides smooth estimations and enables the estimation of 
the net probability of developing cancer, particularly by birth cohort. This indicator is 
especially valuable in providing synthetic information regarding incidence trends by birth 
cohort.  
The main limitation of the present study is the difficulty in determining which cancers were 
associated with HPV. HPV has been recognised only since 2007 by the IARC as a risk factor 
for tonsil and pharynx cancers. Its detection is not recommended in France; therefore, actual 
HPV status is not known. Our classification of HNC subsites relied on the potential of being 
related to HPV, based on etiologic evidence and previous study. HPV can’t be thus totally 
excluded from the carcinogenicity of the HPV-Unr HNC : the number of cancers attributable 
to HPV is estimated to 4.3% for the oral cavity cancer (base of tongue excluded) and 4.6% 
for the cancer of the larynx22. Similarly, due to the high prevalence, in France, of the two 
main risk factors of HNC i.e. tobacco and alcohol, the HPV-R group is actually highly 
contaminated by cancers unrelated to HPV. This would explain for instance, the decrease in 
HPV-R cancers observed in men. Yet it is possible to comment and try to interpret the 
differences in trends between the two groups, with respect to our knowledge regarding 
trends in other risk factors. Tobacco consumption and alcohol drinking habits are not 
collected by cancer registries because these data are not available from the medical records. 
The distribution of these main risk factors for each HNC is unknown; however, changes in 
their consumption in France may suggest the role of another risk factor in the epidemiological 
pattern observed. 
Another limitation of the study is the extension of the results to all of France: we used 
observed data issued from 11 general cancers registries which cover approximately 14% of 
the French metropolitan population. These registries do not cover major urban centres, 
where the incidence trends may be quite different. They meet high-quality criteria and are 
certified every four years by the National Institute of Health and Medical Research 
(INSERM), the French Institute for Public Health Surveillance (Santé Publique France) and 
the French National Cancer Institute (INCa, Institut National du Cancer). 
 
To check results, a sensitivity analysis has been done by forcing the model on the HPV-R 
groups (for both men and women) to include a period term p2 (thus using the same model as 
for the HPV-Unr HNC groups) and then computed the ratio of net probability of developing 
cancer between 0 and 74 years for HPV-R vs HPV-Unr HNC in both sex. The results of this 
sensitivity were almost identical to those depicted on Figure 3, reinforcing the robustness of 
our findings. 
 
Trends of incidence of HPV-Unr HNC 
The procedures for diagnosis, notification process and HNC recording did not change during 
the study period, so it is unlikely that the observed trends are a result of period effect. These 
trends call for an examination of the main factors associated with HNC; namely, alcohol and 
tobacco, whose consumption has regularly decreased.  
The decrease in alcohol consumption has been observed in both sexes since the thirties-
forties but men’s consumption is 3 fold higher than women’s consumption 23. The mean 
consumption in France in 1961 was 26 litres of pure alcohol per person per year24; which was 
extremely high compared to alcohol consumption in other countries at the same period2. That 
consumption had decreased to 11.6 litres in 201324. In 2014, 14.6% of men and 4.9% of 
women were daily alcohol consumers25.  
Concerning tobacco, the prevalence of regular smoking in the general population has been 
regularly decreasing in men: 72% in 195326 vs. 32% in 201027. This prevalence has been 
increasing in women (17% in 195326 vs. 26% in 201027), with a period of stabilization or 
decrease between 1990 and 200527, 28.  
These decreases in alcohol and tobacco consumption may explain the decrease of HNC 
incidence observed among men since the cohort born in 1930. 
The rise in tobacco consumption amongst women is a factor in the increased incidence of 
HNC. However, the incidence of HNC in women has not reached the same rate as that 
observed in men, as tobacco and alcohol consumption has nevertheless remained inferior to 
that of men.  
Tobacco consumption in women probably cannot explain the more rapid rise in HPV-R 
cancers in relation to HPV-Unr cancers, particularly as, according to certain authors, HNC 
sites preferentially associated with tobacco consumption are the floor of the mouth 29, 30, 
hypopharynx 29 and larynx 29, 31.  
Among women, incidence rates of HPV-Unr HNC remained stable over the most recent 
period. This result needs to be confirmed in the coming years because the same 
phenomenon has not been observed for other cancers with the same risk factors. These 
include lung cancer and oesophageal cancer, for which the APC for 2005-2012 were +5.4% 
and +1.1% respectively 15.  
 
Trends of incidence of HPV-R HNC 
Some studies have shown an increase in the incidence of HPV-R HNC in both sexes and 
especially for patients aged less than 60 years, whereas the incidence of other HNC is 
decreasing or constant. 
Thus, Chaturvedi et al. 19 showed with data from the SEER program that patients with HPV-R 
oral squamous cell carcinomas (OSCC) were younger and more likely to be men. The 
increase in HPV-R incidence was accompanied by a decrease in HPV-Unr OSCC. The 
increase in incidence was observed among the age groups 40-49 (period 1975-2004) and 
50-59 years (period 2000-2004) and in recent birth cohorts. Forte et al. 6 showed with data 
obtained from the Canadian Cancer Registry that HPV-R oropharyngeal cancers increased 
among men and women, whereas overall HNC decreased among men and remained stable 
among women. The increase in HPV-R oropharyngeal cancers was observed for all age 
groups and was highest for patients aged 50-59 from 1997 to 2009. Blomberg et al. 21 
showed with data from the Danish Cancer Registry an increasing incidence in men (more 
marked for patients <60 years) for HPV-associated and potentially HPV-associated HNC, 
while the incidence of HPV-Unr HNC decreased during the study period (1978-2007). In 
women, a significant increase of HPV-associated HNC was observed, while potentially HPV-
associated and HPV-Unr HNC showed a slight increase.  
Our study shows epidemiological trends consistent with these papers. However, we did not 
see any increase in the incidence of HPV-R HNC in men, probably because incidence rates 
in France were considerably higher during the eighties than in those countries where an 
epidemiological evolution in HNC linked to HPV has been demonstrated 32. Thus, the 
evolution of incidence rate in France is still very much linked to alcohol and tobacco 
consumption, which could be masking the impact of HPV. 
In parallel, the prevalence of HPV in HNC is not yet very high in France. A study reported an 
overall HPV prevalence of 46.5% (PCR) in oropharyngeal cancer (53.7%-tonsil, 30.2%-base 
of tongue) for the period 2000-200916. A second and a third studies reported an HPV 
prevalence in oropharyngeal cancer of 50% (detection of p16 expression using 
immunohistochemistry)-65% (PCR) for the period 2007-200913 and of 30.4% for the period 
2007-201017. By contrast, in Sweden, the prevalence of HPV (PCR) in tonsil cancer was 
evaluated at 93% in 2006–200711 and at 84% in 2004–20078 in base of the tongue cancer. 
In our study, there was a difference in the trend between the two groups of cancers, which 
was more marked among women. This result is compatible with studies of prevalence of 
HPV in HNC in France: in the period 2000-2009, the prevalence of the virus (PCR) was 
significantly higher in women compared with men, 80% vs 52% 33 and 63.5% vs 42.2% 16 
respectively for tonsils and oropharynx.  
 
A positive association exists between the risk of HPV-16-positive oropharyngeal cancer and 
lifetime number of vaginal and/or oral sex partners, engagement in casual sex, early age at 
first intercourse, and infrequent use of condoms 34-36. In France, changes in sexual behaviour 
between 1970 and 2006 matched the increased risk of HNC linked to HPV 37 : the median 
age of first intercourse went down respectively in men and women from 18.8 years and 20.6 
years in 1950 to 17.2 years and 17.6 years in 2000. The average lifetime number of sexual 
partners among men has remained stable (11.6) but has increased among women (1.8 to 
4.4), with a more notable rise in women in the 30-49 year age group (1.9 to 5.1). Engaging in 
oral sex at least once during a lifetime went up to over 80% in 2006 amongst men and 
women, whereas in 1970 it was less than 60%. 
However, the prevalence of HPV 16 in the cervix is lower in western Europe (1.6%) 
compared with North America (4.1%) and northern Europe (3.0%) 38.  
 
Apart from its association with oropharyngeal cancers, HPV is a risk factor for anal canal 
cancers, the incidence of which is increasing in France39, with a greater rise during the period 
2005-2012 in men (APC:+2.6%) and in women (APC:+3.4%).  
 
Thus, the observed changes in the epidemiology of HNC show that at least some of these 
cancers are very probably linked to HPV. This is consistent with observations made in other 
countries, with the few French studies on prevalence of HPV in HNC and also with the 
evolution of sexual behaviour in France. 
 
Conclusion 
The differences in trends between possible HPV-related and HPV-unrelated HNC suggest an 
increasing incidence of HNC due to HPV infection in France. Among men, differences are 
less marked, probably because of a higher contamination of tobacco and alcohol-related 
cancers in the HPV-related group. Future epidemiological patterns of these cancers should 
also be discussed by taking into account the sexual behaviour during the AIDS epidemic, 
“binge-drinking” alcohol consumption and the impact of the vaccination program for the 
prevention of cervical cancer. 
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Figure1: Human papilloma virus-related and -unrelated head and neck cancers age-
standardised incidence rates by sex: trends from 1980 to 2012, France (logarithmic scale) 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Net probability of developing cancer between 0 and 74 years according to birth 
cohort for human papilloma virus(HPV)-related head and neck cancers and HPV-unrelated 
and by sex 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Ratio of net probability of developing cancer between 0 and 74 years for human 
papilloma virus (HPV)-related head and neck cancers / HPV-unrelated by birth cohort and 
sex 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Head and neck cancer incidence rates according to age by birth cohort and sex: 
Human papilloma virus(HPV)-related cancers and men (A), HPV-related cancers and women 
(B), HPV-unrelated cancers and men (C), HPV-unrelated cancers and women (D) 
 
 
 
